Literature DB >> 2137008

Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret.

J Hawthorn1, D Cunningham.   

Abstract

A new group of selective 5HT3 antagonists are proving to be effective anti-emetics for cytotoxic and radiation induced vomiting in both animal models and man. Current anti-emetic regimens often benefit from combination therapy, in particular the efficacy of metoclopramide (which can be a weak 5HT3 antagonist), can be improved by combination with dexamethasone, another anti-emetic. Hence it was of interest to evaluate whether a 5HT3 receptor antagonist GR38032F could be improved by combination with dexamethasone. Vomiting induced by cyclophosphamide in the ferret was observed after pre-treatment with dexamethasone alone or in combination with GR38032F. Animals were also observed for signs of 'nausea'. Dexamethasone alone proved a weak anti-emetic in this system but did have significant effects on 'nausea'. GR38032F has previously been shown to be capable of totally controlling emesis due to cyclophosphamide in the ferret. Here a dose of GR38032F that is not 100% effective was employed; this was shown to have effects on 'nausea' but most interestingly its anti-emetic action was increased by combination with dexamethasone. This may be important for the minority of patients whose vomiting is not completely controlled by GR38032F alone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137008      PMCID: PMC1971346          DOI: 10.1038/bjc.1990.12

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.

Authors:  D Cunningham; A Turner; J Hawthorn; R D Rosin
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.

Authors:  U Leibundgut; I Lancranjan
Journal:  Lancet       Date:  1987-05-23       Impact factor: 79.321

3.  Antiemetic properties of the 5HT3-receptor antagonist, GR38032F.

Authors:  R Stables; P L Andrews; H E Bailey; B Costall; S J Gunning; J Hawthorn; R J Naylor; M B Tyers
Journal:  Cancer Treat Rev       Date:  1987-12       Impact factor: 12.111

4.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

5.  Radiation-induced emesis in the dog: effects of lesions and drugs.

Authors:  D O Carpenter; D B Briggs; A P Knox; N L Strominger
Journal:  Radiat Res       Date:  1986-12       Impact factor: 2.841

6.  Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Authors:  W D Miner; G J Sanger
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

7.  Evidence for an extra-abdominal site of action for the 5-HT3 receptor antagonist BRL24924 in the inhibition of radiation-evoked emesis in the ferret.

Authors:  P L Andrews; J Hawthorn
Journal:  Neuropharmacology       Date:  1987-09       Impact factor: 5.250

8.  Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Authors:  D Cunningham; J Hawthorn; A Pople; J C Gazet; H T Ford; T Challoner; R C Coombes
Journal:  Lancet       Date:  1987-06-27       Impact factor: 79.321

9.  A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.

Authors:  C F Pollera; M Nardi; P Marolla; P Carlini
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam.

Authors:  M C Palmer; B M Colls
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more
  12 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Biological Effects of Space Radiation and Development of Effective Countermeasures.

Authors:  Ann R Kennedy
Journal:  Life Sci Space Res (Amst)       Date:  2014-04-01

3.  Cisplatin-induced early and delayed emesis in the pigeon.

Authors:  S Tanihata; H Igarashi; M Suzuki; T Uchiyama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 4.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 5.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

6.  An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats.

Authors:  R H Scott; A J Woods; M J Lacey; D Fernando; J H Crawford; P L Andrews
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

Review 7.  Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.

Authors:  A Del Favero; F Roila; M Tonato
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

8.  An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.

Authors:  J A Rudd; R J Naylor
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

9.  Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

Authors:  J F Smyth; R E Coleman; M Nicolson; W M Gallmeier; R C Leonard; M A Cornbleet; S G Allan; B K Upadhyaya; U Bruntsch
Journal:  BMJ       Date:  1991-12-07

10.  Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.

Authors:  E Campora; C Oliva; S Mammoliti; G L Cetto; V Fosser; M Marangolo; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.